Literature DB >> 28795849

Doxorubicin-conjugated D-glucosamine- and folate- bi-functionalised InP/ZnS quantum dots for cancer cells imaging and therapy.

Zahra Ranjbar-Navazi1,2, Morteza Eskandani2, Mohammad Johari-Ahar2,3, Ali Nemati4, Hamid Akbari5, Soudabeh Davaran2, Yadollah Omidi2,6.   

Abstract

Nanoscaled quantum dots (QDs), with unique optical properties have been used for the development of theranostics. Here, InP/ZnS QDs were synthesised and functionalised with folate (QD-FA), D-glucosamine (QD-GA) or both (QD-FA-GA). The bi-functionalised QDs were further conjugated with doxorubicin (QD-FA-GA-DOX). Optimum Indium to fatty acid (In:MA) ratio was 1:3.5. Transmission electron microscopy (TEM) micrographs revealed spherical morphology for the QDs (11 nm). Energy-dispersive spectroscopy (EDS) spectrum confirmed the chemical composition of the QDs. MTT analysis in the OVCAR-3 cells treated with bare QDs, QD-FA, QD-GA, QD-FA-GA and QD-FA-GA-DOX (0.2 mg/mL of QDs) after 24 h indicated low toxicity for the bare QDs and functionalised QDs (about 80-90% cell viability). QD-FA-GA-DOX nanoparticles elicited toxicity in the cells. Cellular uptake of the engineered QDs were investigated in both folate receptor (FR)-positive OVCAR-3 cells and FR-negative A549 cells using fluorescence microscopy and FACS flow cytometry. The FA-functionalised QDs showed significantly higher uptake in the FR-positive OVCAR-3 cells, nonetheless the GA-functionalised QDs resulted in an indiscriminate uptake in both cell lines. In conclusion, our findings indicated that DOX-conjugated FA-armed QDs can be used as theranostics for simultaneous imaging and therapy of cancer.

Entities:  

Keywords:  InP/ZnS quantum dots; folic acid; solid tumours; targeted drug delivery; theranostics

Mesh:

Substances:

Year:  2017        PMID: 28795849     DOI: 10.1080/1061186X.2017.1365876

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  5 in total

Review 1.  Current role of nanoparticles in the treatment of lung cancer.

Authors:  Eliseo Carrasco-Esteban; José Antonio Domínguez-Rullán; Patricia Barrionuevo-Castillo; Lira Pelari-Mici; Olwen Leaman; Sara Sastre-Gallego; Fernando López-Campos
Journal:  J Clin Transl Res       Date:  2021-03-16

2.  Mucin-1 aptamer-armed superparamagnetic iron oxide nanoparticles for targeted delivery of doxorubicin to breast cancer cells.

Authors:  Ayuob Aghanejad; Hiwa Babamiri; Khosro Adibkia; Jaleh Barar; Yadollah Omidi
Journal:  Bioimpacts       Date:  2018-05-05

3.  Enzyme replacement therapies: what is the best option?

Authors:  Azam Safary; Mostafa Akbarzadeh Khiavi; Rahimeh Mousavi; Jaleh Barar; Mohammad A Rafi
Journal:  Bioimpacts       Date:  2018-07-07

4.  TEM1-targeting PEGylated PLGA shikonin nanoformulation for immunomodulation and eradication of ovarian cancer.

Authors:  Efthymia-Iliana Matthaiou; Yi Guo; Jaleh Barar; Raphael Sandaltzopoulos; Lana E Kandalaft; Chunsheng Li; George Coukos; Yadollah Omidi
Journal:  Bioimpacts       Date:  2021-12-19

5.  Enhanced Tumor Imaging Using Glucosamine-Conjugated Polyacrylic Acid-Coated Ultrasmall Gadolinium Oxide Nanoparticles in Magnetic Resonance Imaging.

Authors:  Shuwen Liu; Huan Yue; Son Long Ho; Soyeon Kim; Ji Ae Park; Tirusew Tegafaw; Mohammad Yaseen Ahmad; Seungho Kim; Abdullah Khamis Ali Al Saidi; Dejun Zhao; Ying Liu; Sung-Wook Nam; Kwon Seok Chae; Yongmin Chang; Gang Ho Lee
Journal:  Int J Mol Sci       Date:  2022-02-04       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.